ADER, Florence, Nathan PEIFFER-SMADJA, Julien POISSY, Maude BOUSCAMBERT-DUCHAMP, Drifa BELHADI, Alpha DIALLO, Christelle DELMAS, Juliette SAILLARD, Aline DECHANET, Noémie MERCIER, Axelle DUPONT, Toni ALFAIATE, François-Xavier LESCURE, François RAFFI, François GOEHRINGER, Antoine KIMMOUN, Stéphane JAUREGUIBERRY, Jean REIGNIER, Saad NSEIR, François DANION, Raphael CLERE-JEHL, Kévin BOUILLER, Jean-Christophe NAVELLOU, Violaine TOLSMA, André CABIE, Clément DUBOST, Johan COURJON, Sylvie LEROY, Joy MOOTIEN, Rostane GACI, Bruno MOURVILLIER, Emmanuel FAURE, Valérie POURCHER, Sébastien GALLIEN, Odile LAUNAY, Karine LACOMBE, Jean-Philippe LANOIX, Alain MAKINSON, Guillaume MARTIN-BLONDEL, Lila BOUADMA, Elisabeth BOTELHO-NEVERS, Amandine GAGNEUX-BRUNON, Olivier EPAULARD, Lionel PIROTH, Florent WALLET, Jean-Christophe RICHARD, Jean REUTER, Thérèse STAUB, Maya HITES, Marion NORET, Claire ANDREJAK, Gilles PEYTAVIN, Bruno LINA, Dominique COSTAGLIOLA, Yazdan YAZDANPANAH, Charles BURDET and France MENTRE. Antiviral drugs in hospitalized patients with COVID-19 - the DisCoVeRy trial. medRxiv 20218149 [Preprint]. London: Cold Spring Harbor Laboratory Press, 2021, vol. 2021, No 1, p. 1-31. ISSN 1756-1833. Available from: https://dx.doi.org/10.1101/2021.01.08.20248149.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Antiviral drugs in hospitalized patients with COVID-19 - the DisCoVeRy trial
Authors ADER, Florence, Nathan PEIFFER-SMADJA, Julien POISSY, Maude BOUSCAMBERT-DUCHAMP, Drifa BELHADI, Alpha DIALLO, Christelle DELMAS, Juliette SAILLARD, Aline DECHANET, Noémie MERCIER, Axelle DUPONT, Toni ALFAIATE, François-Xavier LESCURE, François RAFFI, François GOEHRINGER, Antoine KIMMOUN, Stéphane JAUREGUIBERRY, Jean REIGNIER, Saad NSEIR, François DANION, Raphael CLERE-JEHL, Kévin BOUILLER, Jean-Christophe NAVELLOU, Violaine TOLSMA, André CABIE, Clément DUBOST, Johan COURJON, Sylvie LEROY, Joy MOOTIEN, Rostane GACI, Bruno MOURVILLIER, Emmanuel FAURE, Valérie POURCHER, Sébastien GALLIEN, Odile LAUNAY, Karine LACOMBE, Jean-Philippe LANOIX, Alain MAKINSON, Guillaume MARTIN-BLONDEL, Lila BOUADMA, Elisabeth BOTELHO-NEVERS, Amandine GAGNEUX-BRUNON, Olivier EPAULARD, Lionel PIROTH, Florent WALLET, Jean-Christophe RICHARD, Jean REUTER, Thérèse STAUB, Maya HITES, Marion NORET, Claire ANDREJAK, Gilles PEYTAVIN, Bruno LINA, Dominique COSTAGLIOLA, Yazdan YAZDANPANAH, Charles BURDET and France MENTRE.
Edition medRxiv 20218149 [Preprint], London, Cold Spring Harbor Laboratory Press, 2021, 1756-1833.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30230 Other clinical medicine subjects
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW DisCoVeRy trial
Impact factor Impact factor: 93.333
RIV identification code RIV/00216224:14110/21:00124332
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1101/2021.01.08.20248149
Keywords (in Czech) COVID-19; SARS-CoV-2; hydroxychloroquine; interferon beta-1a; lopinavir/ritonavir; randomized controlled trial
Keywords in English COVID-19; SARS-CoV-2; hydroxychloroquine; interferon beta-1a; lopinavir/ritonavir; randomized controlled trial
Tags Excelence Science, INT, MU, RIV, user
Tags International impact
Changed by Changed by: Bc. Hana Vladíková, BBA, učo 244692. Changed: 1/3/2022 12:35.
Abstract
Background Lopinavir/ritonavir, lopinavir/ritonavir-interferon (IFN)-β-1a and hydroxychloroquine efficacy for COVID-19 have been evaluated, but detailed evaluation is lacking. Objective To determine the efficacy of lopinavir/ritonavir, lopinavir/ritonavir-IFN-β-1a, hydroxychloroquine or remdesivir for improving the clinical, virological outcomes in COVID-19 inpatients. Design Open-label, randomized, adaptive, controlled trial.
Links
90128, large research infrastructuresName: CZECRIN III
PrintDisplayed: 28/6/2024 15:10